Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Post-launch report

Post-launch report

Company Product Indication 2006 approval Sales through Sep 30 (A)
Amgen (NASDAQ:AMGN) Vectibix panitumumab Metastatic colorectal cancer U.S. $137.0
Amylin (NASDAQ:AMLN)/ Eli Lilly (NYSE:LLY) Byetta exenatide Type II diabetes where metformin and/or sulfonylurea not adequate; Type II diabetes where

Read the full 425 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers